Table 1. Univariate analysis of clinical variables associated with recurrence and survival.
| Variables | No | OS | DFS | ||
|---|---|---|---|---|---|
| median time to event | P | median time to event | P | ||
| Age: | |||||
| ≤ 50 years | 75 | 39.39 ± 2.75 | 0.18 | 31.57 ± 3.08 | 0.32 |
| > 50 years | 84 | 35.25 ± 2.56 | 27.86 ± 2.92 | ||
| Sex: | |||||
| Female | 32 | 40.41 ± 4.47 | 0.42 | 37.744 ± 5.006 | 0.13 |
| Male | 127 | 36.59 ± 2.06 | 27.973 ± 2.314 | ||
| Total bilirubin: | |||||
| ≤ 17.1μmol/ L | 126 | 36.81 ± 2.10 | 0.62 | 28.76 ± 2.37 | 0.45 |
| > 17.1μmol/L | 33 | 38.69 ± 4.20 | 33.09 ± 4.73 | ||
| ALB: | |||||
| ≤ 40g/ L | 67 | 35.64 ± 3.09 | 0.60 | 33.56 ± 3.43 | 0.17 |
| > 40g/L | 92 | 38.38 ± 2.34 | 26.88 ± 2.66 | ||
| ALT: | |||||
| ≤ 40U/ L | 111 | 37.04 ± 2.24 | 0.99 | 27.93 ± 2.48 | 0.27 |
| > 40U/L | 48 | 37.43 ± 3.46 | 32.83 ± 3.90 | ||
| AST: | |||||
| ≤ 40U/ L | 116 | 35.86 ± 2.17 | 0.19 | 27.55 ± 2.41 | 0.16 |
| > 40U/L | 43 | 40.90 ± 3.68 | 35.60 ± 4.25 | ||
| AFP: | |||||
| < 20 μg/L | 121 | 38.41 ± 2.18 | 0.16 | 31.88 ± 2.42 | 0.03 |
| ≥ 20 μg/L | 38 | 33.37 ± 3.59 | 21.68 ± 4.20 | ||
| CA19-9: | |||||
| ≤ 37 U/ml | 63 | 37.63 ± 3.03 | 0.68 | 30.40 ± 3.39 | 0.50 |
| > 37 U/ml | 96 | 36.83 ± 2.39 | 28.56 ± 2.73 | ||
| CEA | |||||
| ≤ 5 ng/ml | 53 | 36.25 ± 3.37 | 0.83 | 28.77 ± 3.64 | 0.78 |
| > 5 ng/ml | 106 | 37.47 ± 2.27 | 29.80 ± 2.64 | ||
| HBeAg: | |||||
| Negative | 126 | 37.39 ± 2.17 | 0.56 | 30.56 ± 2.41 | 0.38 |
| Positive | 33 | 35.94 ± 3.61 | 24.31 ± 3.93 | ||
| HBsAg: | |||||
| Negative | 73 | 36.39 ± 2.81 | 0.64 | 30.92 ± 3.14 | 0.47 |
| Positive | 86 | 37.85 ± 2.53 | 28.45 ± 2.88 | ||
| HCV: | |||||
| Negative | 130 | 39.01 ± 2.00 | 0.04 | 30.02 ± 2.30 | 0.39 |
| Positive | 29 | 28.96 ± 4.81 | 28.35 ± 5.54 | ||
| Diameter: | |||||
| ≤ 5 cm | 78 | 42.92 ± 2.45 | 0.01 | 34.68 ± 2.94 | 0.01 |
| > 5 cm | 81 | 31.53 ± 2.68 | 24.38 ± 2.96 | ||
| Tumor Number: | |||||
| Single | 131 | 37.83 ± 2.08 | 0.44 | 30.85 ± 2.37 | 0.13 |
| Multiple | 28 | 35.06 ± 4.32 | 24.57 ± 4.63 | ||
| Pathological satellite: | |||||
| No | 104 | 40.68 ± 2.27 | 0.01 | 33.21 ± 2.61 | 0.01 |
| Yes | 55 | 30.93 ± 3.16 | 22.33 ± 3.40 | ||
| Encapsulation: | |||||
| No | 24 | 40.05 ± 4.90 | 0.40 | 35.10 ± 5.55 | 0.17 |
| Complete | 135 | 36.67 ± 2.03 | 28.48 ± 2.28 | ||
| Microvascular invasion: | |||||
| No | 99 | 39.01 ± 2.34 | 0.20 | 33.95 ± 2.66 | 0.01 |
| Yes | 60 | 33.95 ± 3.12 | 22.45 ± 3.32 | ||
| Cirrhosis: | |||||
| No | 51 | 31.86 ± 3.40 | 0.06 | 28.23 ± 3.82 | 0.59 |
| Yes | 108 | 39.79 ± 2.21 | 30.21 ± 2.55 | ||
| Differentiation: | |||||
| I–II | 123 | 37.37 ± 2.15 | 0.75 | 30.78 ± 2.43 | 0.26 |
| III–IV | 36 | 36.76 ± 3.85 | 25.88 ± 4.32 | ||
| Lymph node metastasis: | |||||
| No | 118 | 40.22 ± 2.19 | 0.01 | 31.76 ± 2.52 | 0.05 |
| Yes | 41 | 29.41 ± 3.32 | 23.42 ± 3.72 | ||
| TNM stage: | |||||
| I–II | 106 | 44.67 ± 2.12 | 0.00 | 38.09 ± 2.53 | 0.00 |
| III–IV | 53 | 22.18 ± 2.64 | 11.31 ± 2.10 | ||
| STAT3 expression: | |||||
| Low | 83 | 48.45 ± 2.21 | 0.00 | 42.35 ± 2.67 | 0.00 |
| High | 76 | 24.26 ± 2.28 | 15.29 ± 2.40 | ||